Study of V117957 in Overactive Bladder Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

V117957

V117957 1 mg - 1 tablet taken orally at bedtime.

DRUG

Placebo

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.

Trial Locations (12)

11530

AccuMed Research Associates, Garden City

19046

The Clinical Trial Center, LLC, Jenkintown

27103

Unified Women's Clinical Research-Lyndhurst, Winston-Salem

60805

Providea Health Partners, LLC, Evergreen Park

70115

DelRicht Research, New Orleans

71106

Ochsner LSU Health Shreveport - Regional Urology, Shreveport

85715

Arizona Urology Specialists, PLLC, Tucson

90017

Urology Group of Southern California, Los Angeles

90815

ARK Clinical Research, Long Beach

91303

Hope Clinical Research, LLC, Canoga Park

02131

Boston Clinical Trials, Boston

02472

Bay State Clinical Trials, Inc., Watertown

Sponsors
All Listed Sponsors
collaborator

Purdue Pharma LP

INDUSTRY

lead

Imbrium Therapeutics

INDUSTRY

NCT06024642 - Study of V117957 in Overactive Bladder Syndrome | Biotech Hunter | Biotech Hunter